Denied
The Board denied an initial, compensable disability rating for chronic myelogenous leukemia as the evidence did not support a finding that the Veteran's condition was in apparent remission on continuous molecularly targeted therapy with tyrosine kinase inhibitors or required peripheral blood or bone marrow stem cell transplant.
The deciding factor: The evidence showed the Veteran's CML was active but asymptomatic and did not meet the criteria for a compensable rating under Diagnostic Code 7719.
- Claimed conditions
- chronic myelogenous leukemia
- How they argued it
- Direct service connection
- Exposure basis
- None
- Rating assigned
- None in this decision
- Decision date
- February 6, 2025
- Citation
- A25011082
Want to see how appeals like this one tend to go? Appeals like mine
We are not the VA. Veterans’ Rights is an independent resource built for veterans. We are not the U.S. Department of Veterans Affairs, not part of the government, and not endorsed by any government agency.
This is general information, not legal advice. For advice about your own situation, talk to a VA-accredited representative — many help for free.